Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 66, Issue 11, Pages 1473-1484Publisher
SPRINGER
DOI: 10.1007/s00262-017-2040-9
Keywords
Acute myeloid leukemia; Regulatory T cells; IL-2; Immunotherapy
Categories
Funding
- Meda Pharma, Bad Homburg, Germany
- Swedish Research Council
- Swedish Society for Medical Research (SSMF)
- Swedish Cancer Society (Cancerfonden)
- Swedish state via the ALF agreement
- Erna and Victor Hasselblad Foundation
- Torsten and Ragnar Soderberg Foundation
- Assar Gabrielsson Foundation
- Lars Hierta Memorial Foundation
- Lion Cancer Foundation West
- BioCARE-a National Strategic Research Program at University of Gothenburg
- Sahlgrenska Academy at University of Gothenburg
Ask authors/readers for more resources
Regulatory T cells - (Tregs) have been proposed to dampen functions of anti-neoplastic immune cells and thus promote cancer progression. In a phase IV trial (Re: Mission Trial, NCT01347996, http://www.clinicaltrials.gov) 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received ten consecutive 3-week cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) to prevent relapse of leukemia in the post-consolidation phase. This study aimed at defining the features, function and dynamics of Foxp3(+)CD25(high)CD4(+) T-regs during immunotherapy and to determine the potential impact of T-regs on relapse risk and survival. We observed a pronounced increase in T-reg counts in peripheral blood during initial cycles of HDC/IL-2. The accumulating T-regs resembled thymic-derived natural T-regs (nT(regs)), showed augmented expression of CTLA-4 and suppressed the cell cycle proliferation of conventional T cells ex vivo. Relapse of AML was not prognosticated by T-reg counts at onset of treatment or after the first cycle of immunotherapy. However, the magnitude of T-reg induction was diminished in subsequent treatment cycles. Exploratory analyses implied that a reduced expansion of T-regs in later treatment cycles and a short T-reg telomere length were significantly associated with a favorable clinical outcome. Our results suggest that immunotherapy with HDC/IL-2 in AML entails induction of immunosuppressive T-regs that may be targeted for improved anti-leukemic efficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available